William K. Heiden
Independent Chairman of the BoardDr. William K. Heiden, also known as Bill, has been an Independent Chairman of the Board of MacroGenics, Inc. since May 22, 2022. He serves as a Director at Third Pole, Inc. since February 2021 and serves as its Chairman. He is Director of CoreA Therapeutics. Dr. Heiden has experience as a pharmaceutical and biotechnology senior executive. He began his career at Merck (Schering Plough) where he led a of variety of businesses internationally and in the US during the first 15 years of his career. Over the last 15 years he has been a successful CEO in several private and public biotechnology companies. He most recently served as the President and Chief Executive Officer of AMAG Pharmaceuticals, where he built a diverse portfolio of commercial and development-stage products before it was acquired by a private equity firm in 2020. Dr. Heiden was the Chief Executive Officer of AMAG Pharmaceuticals, Inc. from May 14, 2012 to April 28, 2020 and served as its President until April 28, 2020. Dr. Heiden serves as the Managing Director of Vitruvian Pharmaceuticals. Dr. Heiden served as the President of AMAG Pharmaceuticals, Inc. from May 14, 2012 to April 1, 2015. Dr. Heiden served as the Chief Executive Officer and President of GTC Biotherapeutics, Inc. from June 2010 to May 2012. He served as the President and Chief Executive Officer for Elixir Pharmaceuticals, Inc. from September 2004 to December 2008. Dr. Heiden served as the President and Chief Operating Officer at Praecis Pharmaceuticals Inc. from joining on May 9, 2002 to September 3, 2004. Dr. Heiden is an experienced pharmaceutical and biotechnology executive. From 1987 to 2002, he progressed through various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.). He spent 15 years at Schering Plough where he held positions of increasing responsibility including Managing Director of a number of businesses in Europe and Canada, Vice President of Schering’s U.S. cardiovascular business unit. From April 1998 to July 1999, Dr. Heiden served as Vice President of marketing and sales at Key-Acute Coronary Syndromes, (now Millennium Pharmaceuticals, Inc.). He served as Schering's Director of Managed Health Care from 1996 to 1998, with responsibility for all Schering products within Managed Care for a twelve state region. From 1988 to 1996, he held a variety of management roles in Schering's International Division. He served as General Manager for Schering's business in the BeNeLux (Belgium, Netherlands and Luxembourg), Head of prescription product marketing at Schering Canada and General Manager for Schering Belgium. He served as the Chairman of the Board of rEVO Biologics since June 2010. He has been a Director of Atara Biotherapeutics, Inc. since November 23, 2015. He was a Director of AMAG Pharmaceuticals, Inc from May 14, 2012 to April 28, 2020. He served as a Director of rEVO Biologics since October 1, 2009. He served as Director of LFB S.A. and LFB Biotechnologies. He served as Director of Elixir Pharmaceuticals, Inc. since September 2004 and ConjuChem Biotechnologies, Inc., since January 2008. He is a member of the Duke University Healthcare Advisory Club. Dr. Heiden holds an B.A. in Business Administration and finance from the University of Florida, his M.I.M. from the University of Louvain, Louvain, Belgium and an MBA from the Johnson Graduate School of Management, Cornell University. He holds M.I.M. degree from the University of Louvain.
Positions
- Company NameMacroGenics, Inc.Stock CodeMGNXPositionIndependent Chairman of the BoardColleagues
- EBEric Blasius RisserCEO, President & Director
- WKWilliam K. HeidenIndependent Chairman of the Board
- JKJames KarrelsSenior VP & CFO
- EBEzio BonviniSenior VP of Research & Chief Scientific Officer
- ALAraba Lamouse-SmithVice President of Technical Operations
- JSJeffrey Stuart PetersSenior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer
- EMEdward M. HurwitzIndependent Director
- FFFederica F. O'BrienIndependent Director
- MCMeenu Chhabra KarsonIndependent Director
- Company NameAtara Biotherapeutics, Inc.Stock CodeATRAPositionIndependent Director
